中国生物工程杂志

[1] Migone T S, Subramanian G M, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med, 2009, 61(2): 135-144.
[2] Carter P J. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res, 2011, 317:1261-1269.
[3] WHO. General policies for monoclonal antibodies. INN Working Document 09.251. WHO, 24/06/2009.
[4] Seifert G, Jesse P, Laengler A, et a1. Molecular mechanisms of mistletoe plant extract- induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett, 2008, 264(2): 218-228.
[5] Tracey D, Klareskog L, Sasso E H, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther, 2008, 117(2):244-279.
[6] Nurmohamed M T, Dijkmans B A. Are biologics more effective than classical disease- modifying antirheumatic drugs? Arthritis Res Therap, 2008, 10(5): 118.
[7] Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol, 2012, 66(2):241-251.
[8] Tonelli F, Giudici F, Asteria C R. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn’s disease: a pilot study. Dis Colon Rectum, 2012, 55(8): 870-875.
[9] Pomirleanu C, Ancu a C, Macovei L, et al. Prospective study of the efficiency and safety of adalimumab in treatment of active established rheumatoid arthritis. Rev Med Chir Soc Med Nat Iasi, 2012, 116(2): 395-400.
[10] Tracey D, Klareskog L, Sasso E H, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Therap, 2008, 117(2): 244-279.
[11] Demirkaya E, Cok I, Durmaz E, et al. Genotoxicity of antitumor necrosis factor therapy in patients with juvenile idiopathic arthritis. Arthritis Care Res, 2010, 62(1):73-77.
[12] Shale M, Seow C, Coffin C, et al. Review article: chronic viral infection in the antitumor necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Therap, 2010, 31(1): 20-34.
[13] Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood, 2011, 118: 358-367.
[14] Pawluczkowycz A W, Beurskens F J, Beum P V, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol, 2009, 183: 749-758.
[15] Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 2010, 115: 4393-4402.
[16] Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the antilymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther, 2011, 10: 178-185.
[17] Kim G P, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics, 2008, 2: 223-228.
[18] Schneider-Merck T, Lammerts van Bueren J J, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol, 2010, 184: 512-520.
[19] Li S, Kussie P, Ferguson K M. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure, 2008, 16: 216-227.
[20] Dienstmann R, Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther, 2011, 11: 1223-1231.
[21] Strumberg D, Schultheis B, Scheulen M E, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor recep-tor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs, 2012, 30(3):1138-1143.
[22] Garrido G, Tikhomirov I A, Rabasa A, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther, 2011, 11: 373- 382.
[23] Spratlin J L, Cohen R B, Eadens M, et al. Phase I phar-macologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol, 2010, 28: 780-787.
[24] Jäger M, Schoberth A, Ruf P, et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res, 2009, 69(10):4270-4276.
[25] Lu Q, Rouby J J, Laterre P F, et al. Phar-macokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother, 2011, 66: 1110-1116.
[26] Siemers E R, Friedrich S, Dean R A, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol, 2010, 33: 67-73.